Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Dupixent (dupilumab) for treating chronic spontaneous urticaria (CSU) in children aged two to 11 years who have moderate-to-severe symptoms despite treatment with antihistamines [1][2]. Group 1: Product Approval and Clinical Studies - Dupixent's positive opinion is based on data from the LIBERTY-CUPID clinical study program, which includes two phase 3 studies and a single-arm phase 3 study involving children aged two to 11 years [2]. - In the US, a supplemental biologics license application for Dupixent in children aged two to 11 years with CSU has been accepted for review, with a decision expected by April 2026 [3]. Group 2: Disease Background and Treatment Options - Chronic spontaneous urticaria (CSU) is a chronic inflammatory skin disease characterized by debilitating hives and recurring itch, often inadequately controlled by standard antihistamine treatments [5]. - Many patients with CSU experience uncontrolled symptoms despite treatment, leading to a significant impact on their quality of life [5]. Group 3: Dupixent Overview - Dupixent is a fully human monoclonal antibody that inhibits interleukin-4 (IL4) and interleukin-13 (IL13) signaling pathways, which are key drivers of type 2 inflammation [6]. - The drug has received regulatory approvals in over 60 countries for various indications, including CSU, and is currently being used to treat more than 1.4 million patients globally [7]. Group 4: Development and Future Prospects - Dupilumab is being jointly developed by Sanofi and Regeneron, with over 60 clinical studies involving more than 12,000 patients conducted to date [8]. - Sanofi and Regeneron are exploring additional indications for Dupixent, including chronic pruritus of unknown origin and lichen simplex chronicus, which are currently under clinical investigation [9].

Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Dupixent (dupilumab) for treating chronic spontaneous urticaria (CSU) in children aged two to 11 years who have not responded adequately to standard antihistamine treatment [1][2]. Group 1: Approval and Clinical Studies - The positive CHMP opinion is based on data from the LIBERTY-CUPID clinical study program, which includes two phase 3 studies and a single-arm phase 3 study involving children aged two to 11 years with CSU [2]. - Dupixent is already approved for CSU in certain adults and adolescents in multiple jurisdictions, including the US, EU, and Japan [2]. Group 2: Regulatory Developments - In the US, a supplemental biologics license application for Dupixent in children aged two to 11 years with CSU has been accepted for review, with a decision from the FDA expected by April 2026 [3]. Group 3: Disease Background - Chronic spontaneous urticaria (CSU) is a chronic inflammatory skin disease characterized by debilitating hives and recurring itch, often inadequately controlled by standard antihistamine treatments [5]. - Many patients with CSU experience significant impacts on their quality of life due to uncontrolled symptoms [5]. Group 4: Dupixent Overview - Dupixent is a fully human monoclonal antibody that inhibits interleukin-4 (IL4) and interleukin-13 (IL13) signaling pathways, which are key drivers of type 2 inflammation [6]. - The Dupixent development program has demonstrated significant clinical benefits and a reduction in type 2 inflammation in phase 3 studies [6]. Group 5: Market Presence - Dupixent has received regulatory approvals in over 60 countries for various indications, including atopic dermatitis, asthma, and CSU, with more than 1.4 million patients currently treated globally [7][8].

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for M ...

Core Insights - The FDA has approved Dupixent (dupilumab) as the first and only treatment for allergic fungal rhinosinusitis (AFRS) in patients aged 6 years and older with a history of sino-nasal surgery, marking a significant advancement in the treatment of this condition [2][3][4] Group 1: Approval and Indications - Dupixent is now approved for treating nine distinct diseases driven by type 2 inflammation, including sino-nasal, skin, gut, and respiratory system diseases [6] - The approval was based on the LIBERTY-AFRS-AIMS phase 3 study, which demonstrated significant improvements in sinus opacification scores and nasal symptoms compared to placebo [4][10] Group 2: Clinical Study Results - In the LIBERTY-AFRS-AIMS study, Dupixent improved sinus opacification scores by 50% compared to 10% for placebo at Week 52, with a significant reduction also observed at Week 24 [4][11] - Patient-reported nasal congestion improved by 67% at Week 24 and 81% at Week 52 compared to 25% and 11% for placebo, respectively [7][13] - Dupixent reduced the risk of systemic corticosteroid use and/or surgery by 92%, with only 3% of patients on Dupixent requiring systemic corticosteroids compared to 31% on placebo [13] Group 3: Safety Profile - The safety profile of Dupixent in the LIBERTY-AFRS-AIMS study was consistent with its known safety profile in chronic rhinosinusitis with nasal polyps (CRSwNP), with common adverse reactions including injection site reactions and conjunctivitis [8][9] Group 4: Market Impact and Future Plans - Dupixent's approval is expected to establish a new standard of care for patients with AFRS, addressing a high unmet need in the treatment landscape [9] - Sanofi and Regeneron plan to submit additional applications to regulatory authorities worldwide to expand access to Dupixent [9][17]

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placeboAFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurr ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 inflammation, i ...

Leadership Change - Sanofi has announced the appointment of Belén Garijo as the new CEO, succeeding Paul Hudson, whose contract will not be renewed [1] - Garijo, currently the CEO of Merck KGaA, will assume her new role on April 29, 2026, after a five-year tenure at Merck KGaA [2] Financial Performance - Sanofi's vaccine revenue dropped by 5% in 2025, generating €7.9 billion compared to €8.3 billion in 2024, while overall net sales grew by 9.9% at constant exchange rates to reach €43.6 billion ($51.7 billion) [4] - The company is preparing for the loss of patent protection for Dupixent, which generated €14.7 billion last year [5] Challenges and Pipeline Issues - Sanofi is facing challenges in the US vaccine sector due to policy changes under the Trump administration, impacting immunization recommendations and new candidate approvals [3] - Recent pipeline disappointments include FDA rejections and failures in multiple sclerosis treatments, as well as mixed results for COPD candidates [6] Strategic Focus - Garijo's primary focus will be on enhancing the productivity, governance, and innovation capacity of Sanofi's R&D [7]

Core Insights - Regeneron Pharmaceuticals is set to present 36 abstracts at the 2026 AAAAI Annual Meeting, highlighting new Phase 3 data for investigational allergen-blocking antibodies targeting cat and birch allergies, as well as new insights on Dupixent's efficacy across various diseases [1][2] Regeneron's Pipeline and Research - The company is pioneering first-in-class treatments for cat and birch allergies, with Phase 3 data demonstrating the potential to alleviate ocular symptoms in adults [2][3] - Additional registration-enabling trials for these allergy treatments are planned for this year, aiming to evaluate similar endpoints over longer follow-up periods [3] - Regeneron's broader allergy pipeline includes innovative strategies aimed at eliminating all IgE-mediated allergies [3] Dupixent Insights - New analyses on Dupixent will be presented, focusing on its impact on allergy sensitization in children with atopic dermatitis, measuring IgE levels for various allergens over a treatment period of up to 1.5 years [4] - Real-world analyses will assess the potential benefits of initiating Dupixent earlier in asthma treatment, comparing its effects on exacerbation rates and corticosteroid use against other treatment options [5] - Late-breaking data from the Phase 3 AIMS trial for allergic fungal rhinosinusitis (AFRS) will also be shared, which supports a supplemental Biologics License Application currently under Priority Review [6] Presentation Details - The full list of Regeneron's presentations at the AAAAI includes various studies on allergic inflammation, immunological evaluations, and the efficacy of antibody cocktails in treating allergic conditions [7][8]

Regeneron Corporate Presentation J A N U A R Y 2 0 2 6 2 Integrating Genetics, Proteomics, and Big Data World's largest DNA and proteomics-linked healthcare database, enabling advanced drug discovery, development, and healthcare analytics This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that i ...

Core Insights - Kymera Therapeutics, Inc. (KYMR) has experienced a significant stock performance increase of 82.4% over the past year, outperforming the industry gain of 17.3% and the S&P 500 Index [1][2] Pipeline and Clinical Developments - Kymera is advancing its lead pipeline candidate KT-621, a first-in-class oral degrader of STAT6, aimed at treating type 2 inflammatory diseases [5][10] - Positive results from the phase Ib BroADen study for KT-621 showed deep STAT6 degradation, with median reductions of 94% in skin and 98% in blood [6][9] - The treatment also resulted in a mean 63% reduction in the Eczema Area and Severity Index (EASI) and a mean 40% reduction in peak pruritus Numerical Rating Scale (NRS) [8][10] - KT-621 has received FDA Fast Track designation and is currently undergoing a phase IIb study for atopic dermatitis, with data expected by mid-2027 [11][12] Strategic Partnerships - Kymera has entered into a collaboration with Gilead Sciences to develop a novel molecular glue degrader program targeting CDK2 for oncology applications [13][14] - The company also collaborates with Sanofi, which has prioritized the development of KT-485, a candidate for immuno-inflammatory diseases, over KT-474 [15][16] Valuation and Financial Estimates - KYMR's shares are currently trading at a price/book ratio of 5.53X, which is higher than the biotech industry average of 3.61X [17] - The Zacks Consensus Estimate for 2025 loss per share has widened, while the estimate for 2026 loss has narrowed to $3.64 [19][20] Investment Recommendations - Existing investors are advised to hold the stock, while prospective investors should wait for a more favorable entry point [21][22]